Metallothioneins and oncology

Metallothioneins in Biochemistry and Pathology

Volumn , Issue , 2008, Pages 141-166

  Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cancer; Drug resistance; Metallothioneins; Prognosis; Radiotherapy resistance

Indexed keywords

EID: 84969625970     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812778949_0007     Document Type: Chapter

References (117)

1. Abdel-Mageed A, Agrawal KC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 1997; 4: 199-207.
2. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987; 19: 149-154.
3. Aroni K, Theocharis S, Tsagroni E, Davaris P. Immunohistochemical expression of metallothionein in different dermal lesions. Arch Anat Cytol Pathol Clin Exp Pathol 1998; 46: 344.
4. Bahnson RR, Becich M, Ernstoff MS, et al. Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. J Urol 1994; 152: 2272-2275.
5. Bay B-H, Jin R, Huang J, Tan P-H. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med 2006; 231: 1516-1521.
6. Bouzourene H, Chaubert P, Gebhard S, et al. Role of metallothionein in irradiated human rectal carcinoma. Cancer 2002; 95: 1003-1008.
7. Cai L, Satoh M, Tohyama C, Cherian MG. Metallothionein in radiation exposure: Its induction and protective role. Toxicology 1999; 132: 85-98.
8. Cheng TC, Manorek G, Samimi G, et al. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006; 58: 384-385.
9. Cherian G, Howell SB, Imura N, et al. Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 1994; 126: 1-5.
10. Chin JL, Banerjee D, Kadhim SA, et al. Metallothionein in testicular germ cell tumors and drug resistance. Cancer 1993; 72: 3029-3035.
11. Dutta R, Sens DA, Somji S, et al. Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 2002; 52: 89-97.
12. Eid H, Geczi L, Bodrogi I, et al. Do metallothioneins affect the response to treatment in testis cancers? J Cancer Res Clin Oncol 1998; 124: 31-36.
13. Fresno M, Wu W, Rodriguez JM, Nadji M. Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1993; 423: 215-219.
14. Germain I, Tetu B, Brisson J, et al. Markers of chemoresistance in ovarian carcinomas: An immunohistochemical study of 86 cases. Int J Gynecol Pathol 1996; 15: 54-62.
15. Giuffre G, Barresi G, Sturniolo GC, et al. Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenomas and in adenocarcinomas and their associated metastases. Histopathology 1996; 29: 347-354.
16. Goldmann T, Moorkamp A, Wiedorn KH, et al. The prognostic value of the expression of collagenase IV, cathepsin D and metallothionein in squamous cell carcinomas of the skin determined by immunohistochemistry. Arch Dermatol Res 2001; 293: 115-120.
17. Goldmann T, Ribbert D, Suter L, et al. Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics. J Exp Clin Cancer Res 1998; 17: 483-489.
18. Goulding H, Jasani B, Pereira H, et al. Metallothionein expression in human breast cancer. BrJ Cancer 1995; 72: 968-972.
19. Haerslev T, Jacobsen GK, Zedeler K. The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 1995; 103: 279-285.
20. Haerslev T, Jacobsen K, Nedergaard L, Zedeler K. Immunohistochemical detection of metal lothionein in primary breast carcinomas and their axillary lymph node metastases. Pathol Res Pract 1994; 190: 675-681.
21. Head JF, Elliott RL, Yang DC. Gene targets of antisense therapies in breast cancer. Expert Opin Ther Targets 2002; 6: 375-385.
22. Helleman J, Burger H, Hamelers IH, et al. Impaired cisplatin influx in an A2780 mutant cell line: Evidence for a putative, cis-configuration-specific platinum influx transporter. Cancer Biol Ther 2006; 5: 943-949.
23. Hengstler JG, Pilch H, Schmidt M, et al. Metallothionein expression in ovarian cancer in relation to histopathological parameters and molecular markers of prognosis. Int J Cancer 2001; 95: 121-127.
24. Hishikawa Y, Abe S, Kinugasa S, et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 1997; 54: 342-347.
25. Hishikawa Y, Kohno H, Ueda S, et al. Expression of metallothionein in colorectal cancers and synchronous liver metastases. Oncology 2001; 61: 162-167.
26. Hiura T, Khalid H, Yamashita H, et al. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 1998; 83: 2361-2369.
27. Imagawa M, Ishikawa Y, Shimano H, et al. CTG triplet repeat in mouse growth inhibitory factor/metallothionein III gene promoter represses the transcriptional activity of the heterologous promoters. J Biol Chem 1995; 270: 20898-20900.
28. Ioachim E, Kamina S, Demou A, et al. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, p53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 1999a; 19:2133-2139.
29. Ioachim EE, Goussia AC, Agnantis NJ, et al. Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol 1999b; 52:876-879.
30. Janssen AM, van Duijn W, Kubben FJ, et al. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 2002; 8: 1889-1896.
31. Jasani B, Campbell F, Navabi H, et al. Clonal overexpression of metallothionein is induced by somatic mutation in morphologically normal colonic mucosa. J Pathol 1998; 184: 144-147.
32. Jasani B, Schmid KW. Significance of metallothionein overexpression in human tumours. Histopathology 1997; 31: 211-214.
33. Jayasura A, Bay BH, Yap WM, Tan NG. Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. BrJ Cancer 2000; 82: 1198-1203.
34. Jiang LJ, Maret W, Vallee BL. The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenase. Proc Natl Acad Sci USA 1998; 95: 3483-3488.
35. Joseph MG, Banerjee D, Kocha W, et al. Metallothionein expression in patients with small cell carcinoma of the lung: Correlation with other molecular markers and clinical outcome. Cancer 2001; 92: 836-842.
36. Katoh S, Naito S, Sakamoto N, et al. Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract. J Urol 1994; 152: 1267-1270.
37. Kikuchi Y, Hirata J, Yamamoto K, et al. Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells. Jpn J Cancer Res 1997; 88: 213-217.
38. Kishi K, Doki Y, Miyata H, et al. Prediction of response to chemoradiation and prognosis in oesophageal squamous cancer. BrJSurg 2002; 89: 597-603.
39. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995; 55: 474-477.
40. Kondo Y, Rusnak JM, Hoyt DG, et al. Enhanced apoptosis in metallothionein null cells. Mol Pharmacol 1997; 52: 195-201.
41. Kondoh M, Inoue Y, Atagi S, et al. Specific induction of metallothionein synthesis by mitochondrial oxidative stress. Life Sci 2001; 69: 2137-2146.
42. Koomagi R, Stammler G, Manegold C, et al. Expression of resistance related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett 1996; 110: 129-136.
43. Koropatnick J, Kloth DM, Kadhim S, et al. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J Pharmacol Exp Ther 1995; 275: 1681-1687.
44. Korshunov A, Sycheva R, Timirgaz V, Golanov A. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: An analysis of 76 cases. J Neurooncol 1999; 45: 219-227.
45. Lazo JS, Kuo SM, Woo ES, Pitt BR. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact 1998; 111-112:255-262.
46. Le Beau MM, Diaz MO, Karin M, Rowley JD. Metallothionein gene cluster is split by chromosome 16 rearrangement in myelomonocytic leukaemia. Nature 1985; 313: 709-711.
47. Levadoux-Martin M, Hesketh JE, Beattie JH, Wallace HM. Influence of metallothionein-1 localization on its function. Biochem J 2001; 355: 473-479.
48. Maier H, Jones C, Jasani B, et al. Metallothionein overexpression in human brain tumours. Acta Neuropathol 1997; 94: 599-604.
49. Maret W, Jacob C, Vallee BL, Fischer EH. Inhibitory sites in enzymes: Zinc removal and reactivation by thionein. Proc Natl Acad Sci USA 1999; 96: 1936-1940.
50. Margoshes M, Vallee BC. A cadmium binding protein for equine kidney cortex. J Am Chem Soc 1957; 79: 4813-4814.
51. Masters JR, Thomas R, Hall AG, et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways. Eur J Cancer 1996; 32A:1248-1253.
52. Matsumoto Y, Oka M, Sakamoto A, et al. Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy. Anticancer Res 1997; 17: 3777-3780.
53. Mattern J, Koomagi R, Volm M. Expression of drug resistance gene products during progression of lung carcinomas. Oncol Rep 2002; 9: 1181-1184.
54. McCluggage WG, Maxwell P, Bharucha H. Immunohistochemical detection of metallothionein and MIB1 in uterine cervical squamous lesions. Int J Gynecol Pathol 1998; 17: 29-35.
55. McCluggage WG, Maxwell P, Hamilton PW, Jasani B. High metallothionein expression is associated with features predictive of aggressive behaviour in endometrial carcinoma. Histopathology 1999; 34: 51-55.
56. McCluggage WG, Strand K, Abdulkadir A. Immunohistochemical localization of metal-lothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer 2002; 12: 62-65.
57. McGown AT, Murphy D, Swindell R, et al. Correlation of drug resistance-associated parameters in ovarian tumor biopsies. Int J Gynecol Cancer 1994; 4: 241-249.
58. Meijer C, Timmer A, De Vries EG, et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 2000; 85: 777-781.
59. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S, et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol 2005; 3: 5.
60. Moffatt P, Denizeau F. Metallothionein in physiological and physiopathological processes. Drug Metab Rev 1997; 29: 261-307.
61. Monden N, Abe S, Sutoh I, et al. Prognostic significance of the expression of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 1997; 54: 391-399.
62. Moussa M, Kloth D, Peers G, et al. Metallothionein expression in prostatic carcinoma: Correlation with Gleason grade, pathologic stage, DNA content and serum levels of prostate-specific antigen. Clin Invest Med 1997; 20: 371-380.
63. Murphy D, McGown AT, Crowther D, et al. Metallothionein levels in ovarian tumors before and after chemotherapy. BrJ Cancer 1991; 63: 711-714.
64. Ofner D, Maier H, Riedmann B, et al. Immunohistochemical metallothionein expression in colorectal adenocarcinoma: Correlation with tumour stage and patient survival. Virchows Arch 1994; 425: 491-497.
65. Ohshio G, Imamura T, Okada N, et al. Immunohistochemical study of metallothionein in pancreatic carcinomas. J Cancer Res Clin Oncol 1996; 122: 351-355.
66. Oyama T, Take H, Hikino T, et al. Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 1996; 53: 12-17.
67. Pattanaik A, Shaw CF 3rd, Petering DH, et al. Basal metallothionein in tumors: Widespread presence of apoprotein. J Inorg Biochem 1994; 54: 91-105.
68. Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 2001; 28: 37-44.
69. Saika T, Tsushima T, Ochi J, et al. Over-expression of metallothionein and drug-resistance in bladder cancer. Int J Urol 1994; 1: 135-139.
70. Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis. Cancer Res 1994; 54: 5255-5257.
71. Sauerbrey A, Zintl F, Hermann J, Volm M. Multiple resistance mechanisms in acute non-lymphoblastic leukemia (ANLL). Anticancer Res 1998; 18: 1231-1236.
72. Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann Hematol 1994; 69: 111-115.
73. Schmid KW, Ellis IO, Gee JM, et al. Presence and possible significance of immuno-histochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 1993; 422: 153-159.
74. Sens MA, Somji S, Garrett SH, et al. Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 2001; 159: 21-26.
75. Shimoda R, Achanzar WE, Qu W, et al. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 2003; 73: 294-300.
76. Shnyder SD, Hayes AJ, Pringle J, Archer CW. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 1998; 78: 757-759.
77. Siegsmund MJ, Marx C, Seemann O, et al. Cisplatin-resistant bladder carcinoma cells: Enhanced expression of metallothioneins. Urol Res 1999; 27: 157-163.
78. Siu LL, Banerjee D, Khurana RJ, et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 1998; 4: 559-565.
79. Smith DJ, Jaggi M, Zhang W, et al. Metallothionein and resistance to cisplatin and radiation in prostate cancer. Urology 2006; 67: 1341-1347.
80. Stenram U, Ohlsson B, Tranberg KG. Immunohistochemical expression of metallothionein in resected hepatic primary tumors and colorectal carcinoma metastases. APMIS 1999; 107: 420-424.
81. Suganuma K, Kubota T, Saikawa Y, et al. Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 2003; 94: 355-359.
82. Sugita K, Yamamoto O, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am J Dermatopathol 2001; 23: 29-35.
83. Surowiak P, Materna V, Kaplenko I, et al. Augmented expression of metallothionein and glutathione-S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005; 447: 626-633.
84. Surowiak P, Materna V, Maciejczyk A, et al. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 2007; 450: 279-285.
85. Sutoh I, Kohno H, Nakashima Y, et al. Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers. Dis Colon Rectum 2000; 43: 221-232.
86. Suzuki T, Umeyama T, Ohma C, et al. Immunohistochemical study of metallothionein in normal and benign prostatic hyperplasia of human prostate. Prostate 1991; 19: 35-42.
87. Tan Y, Sinniah R, Bay BH, Singh G. Expression of metallothionein and nuclear size in discrimination of malignancy in mucinous ovarian tumors. Int J Gynecol Pathol 1999a; 18:344-350.
88. Tan Y, Sinniah R, Bay BH, Singh G. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours. J Pathol 1999b; 189:60-65.
89. Tews DS, Fleissner C, Tiziani B, Gaumann AK. Intrinsic expression of drug resistance-associated factors in meningiomas. Appl Immunohistochem Mol Morphol 2001; 9: 242-249.
90. Tews DS, Nissen A, Kulgen C, Gaumann AK. Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 2000; 50: 227-237.
91. Theocharis S, Karkantaris C, Philipides T, et al. Expression of metallothionein in lung carcinoma: Correlation with histological type and grade. Histopathology 2002; 40: 143-151.
92. Theocharis S, Kounelis S, Agapitos E, et al. Expression of metallothionein in malignant transformation of cervical neoplasia: An immunohistochemical study. Virchows Arch 1999; 435: 234.
93. Theocharis S, Liatsos C, Rokkas T, et al. Immunohistochemical expression of metallothionein in colorectal adenomatous polyps. Gastroenterology 1997; 112: A668.
94. Theocharis S, Margeli A, Koutselinis A. Metallothionein: A multifunctional protein from toxicity to cancer. Int J Biol Markers 2003; 18: 162-169.
95. Theocharis SE, Kouraklis GP, Kakisis JD, et al. Metallothionein expression in human gastric cancer. J EurSurg Res 2001; 33: 137.
96. Theocharis SE, Margeli AP, Klijanienko JT, Kouraklis GP. Metallothionein expression in human neoplasia. Histopathology 2004; 45: 103-118.
97. Tsangaris GT, Vamvoukakis J, Politis I, et al. Metallothionein expression prevents apoptosis. II: Evaluation of the role of metallothionein expression on the chemotherapy-induced apoptosis during the treatment of acute leukemia. Anticancer Res 2000; 20: 4407-4411.
98. Tuccari G, Fedele F, Giuffre G, et al. Immunohistochemical demonstration of metallothionein in eyes with choroidal melanomas. Eur J Ophthalmol 2000a; 10:312-317.
99. Tuccari G, Giuffre G, Arena F, Barresi G. Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol Histopathol 2000b; 15:1035-1041.
100. Tuzel E, Kirkali Z, Yorukoglu K, et al. Metallothionein expression in renal cell carcinoma: Subcellular localization and prognostic significance. J Urol 2001; 165: 1710-1713.
101. Uchida Y, Takio K, Titani K, et al. The growth inhibitory factor that is deficient in the Alzheimer’s disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991; 7: 337-347.
102. Uozaki H, Horiuchi H, Ishida T, et al. Overexpression of resistance-related proteins (met-allothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997; 79: 2336-2344.
103. Vazquez-Ramirez FJ, Gonzalez-Campora JJ, Hevia-Alvarez E, et al. P-glycoprotein, metallothionein and NM23 protein expression in breast carcinoma. Pathol Res Pract 2000; 196: 553-559.
104. Volm M, Koomagi R, Mattern J, Efferth T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. BrJ Cancer 2002; 87: 251-257.
105. Volm M, Mattern J. Resistance mechanisms and their regulation in lung cancer. Crit Rev Oncol 1996; 7: 227-244.
106. Volm M, Rittgen W. Cellular predictive factors for the drug response of lung cancer. Anticancer Res 2000; 20: 3449-3458.
107. Weinlich G, Topar G, Eisendle K, et al. Comparison of metallothionein overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol 2007; 21: 669-677.
108. Weinlich G, Zelger B. Metallothionein overexpression, a highly significant prognostic factor in thin melanoma. Histopathology 2007; 51: 280-283.
109. Wood DP Jr, Klein E, Fair WR, Chaganti RS. Metallothionein expression in bladder cancer exposed to cisplatin. Mod Pathol 1993; 6: 33-35.
110. Wrigley E, Verspaget HW, Jayson GC, McGown AT. Metallothionein expression in epithelial ovarian cancer: Effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 2000; 126: 717-721.
111. Wülfing C, van Ahlen H, Eltze E, et al. Metallothionein in bladder cancer: Correlation of overexpression with poor outcome after chemotherapy. World J Urol 2007; 25: 199-205.
112. Yasuno T, Matsumura T, Shikata T, et al. Establishment and characterization of a cisplatin-resistant human neuroblastoma cell line. Anticancer Res 1999; 19: 4049-4057.
113. Zangger K, Oz G, Haslinger E, et al. Nitric oxide selectively releases metals from the aminoterminal domain of metallothioneins: Potential role at inflammatory sites. FASEB J 2001; 15: 1303-1305.
114. Zelger B, Hittmairr A, Schir M, et al. Immunohistochemically demonstrated metallothionein expression in malignant melanoma. Histopathology 1993; 23: 257-263.
115. Zeng J, Heuchel R, Schaffner W, Kagi JHR. Thionein (apoprotein) can modulate DNA binding and transcription activation by zinc finger containing factor SP1. FEBS Lett 1991a; 279:310-312.
116. Zeng J, Vallee BL, Kagi JHR. Zinc transfer from transcription factor IIIA fingers to thionein clusters. Proc Natl Acad Sci USA 1991b; 88:9984-9988.
117. Zhang R, Zhang H, Wei H, Luo X. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol 2000; 19: 95-97.